Name (Synonyms) | Correlation | |
---|---|---|
drug9 | 1: ILT101 Wiki | 1.00 |
drug638 | Lopinavir / Ritonavir Pill Wiki | 1.00 |
drug1082 | Standard treatment Wiki | 0.58 |
drug108 | Azithromycin Wiki | 0.19 |
drug505 | Hydroxychloroquine Wiki | 0.11 |
Name (Synonyms) | Correlation | |
---|---|---|
D055371 | Acute Lung Injury NIH | 0.13 |
D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.13 |
D012128 | Respiratory Distress Syndrome, Adult NIH | 0.11 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose is to demonstrate the efficacy of low-dose interleukin 2 (Ld-IL2) administration in improving clinical course and oxygenation parameters in patients with SARS-CoV2-related ARDS.
Description: To evaluate selected immune and inflammatory markers: Serum concentrations of cytokines and soluble factors related to the immune response and inflammatory processes will be evaluated and compare to baseline by multiplex immunoprofiling to analyse a larger number of molecules including at least IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-6, IL-8, IL-10, IL-17, TNFα, TNFβ, VEGF-A, TGF-beta, S-RAGE, SP-A, SP-D, Angiopoétine 1 and KGF.
Measure: Cytokines analysis on plasma samples at Day 0, 7 and 14 Time: at Day 0, 7 and 14Description: Cellular components will be analysed by flow cytometry covering (i) most of the innate and adaptive immune cells including Tregs, T helper cell subsets including follicular helper cells, B cell subsets, NK cell subsets, (ii) the associated relevant markers of activation/function/differentiation, tissue migration, as well as (iii) unconventional lymphoid cells (NKT/MAIT, innate lymphoid cells), myeloid-derived suppressor cells, classical and non-classical monocytes and dendritic cells (mDC1/2, pDC).
Measure: Deep Immunophenotyping of Cellular components in blood samples at Day 0, 7, and 14 Time: at Day0, 7 and Day14